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RhoA-mediated regulation of myosin-II activity in the
actin cortex controls the ability of cells to contract
and bleb during a variety of cellular processes,
including cell migration and division. Cell contraction
and blebbing also frequently occur as part of the
cytopathic effect seen during many different viral in-
fections. We now demonstrate that the vaccinia virus
protein F11, which localizes to the plasma mem-
brane, is required for ROCK-mediated cell contrac-
tion from 2 hr post infection. Curiously, F11-induced
cell contraction is dependent on RhoC and not
RhoA signaling to ROCK. Moreover, RhoC-driven
cell contraction depends on the upstream inhibition
of RhoD signaling by F11. This inhibition prevents
RhoD from regulating its downstream effector Pak6,
alleviating the suppression of RhoC by the kinase.
Our observations with vaccinia have now demon-
strated that RhoD recruits Pak6 to the plasma mem-
brane to antagonize RhoC signaling during cell
contraction and blebbing.
INTRODUCTION
The cortical actin cytoskeleton consists of a dense network of
actin filaments, crosslinked by myosin-II and other actin-binding
proteins, that is intrinsically linked to the cytoplasmic face of the
plasma membrane (Biro et al., 2013; Charras et al., 2006; Clark
et al., 2013; Fritzsche et al., 2013; Koster and Mayor, 2016; Mo-
rone et al., 2006). The regulation of the density and organization
of actin filaments in the cell cortex, as well as their myosin-II
driven contraction, provides the cell with mechanical resilience
(Bovellan et al., 2014; Clark et al., 2013; Fritzsche et al., 2013,
2016; Gauthier et al., 2012; Salbreux et al., 2012; Tinevez et al.,
2009). It also enables the cortical actin cytoskeleton to regulateDevelopmental Cell 41, 315–329, May 8, 2017
This is an open access article undthe shape of the cell during a variety of cellular processes
including migration, mitotic rounding, and cytokinesis (Friedl
andWolf, 2003; Matthews et al., 2012; Sedzinski et al., 2011; Za-
tulovskiy et al., 2014). A frequent hallmark of myosin-II-driven
contraction of the actin cortex during these cellular processes
is the transient and rapid appearance of spherical blebs on the
plasmamembrane (Charras et al., 2008). Theseprotrusionsoccur
at regions where the plasma membrane separates from the un-
derlying actin cortex because of increased hydrostatic pressure
within the cell (Charras et al., 2008; Paluch et al., 2006; Tinevez
et al., 2009).
Over the last decade, it has become clear that blebbing of the
plasma membrane helps drive ameboid-based cell motility dur-
ing development and tumor cell migration (Blaser et al., 2006;
Charras and Paluch, 2008; Diz-Munoz et al., 2010; Fackler and
Grosse, 2008; Friedl andWolf, 2003; Kardash et al., 2010; Paluch
and Raz, 2013; Sahai and Marshall, 2003; Sanz-Moreno et al.,
2008; Tozluoglu et al., 2013). A key determinant for assembly
and contraction of the actin cortex is the activation of myosin-II
by ROCK-mediated phosphorylation of the myosin light chain
(MLC) (Amano et al., 1997, 1996, 2010; Amin et al., 2013; Sahai
and Marshall, 2003). ROCK also indirectly increases the activ-
ity of myosin-II by inhibiting the MLC phosphatase through
phosphorylation of the myosin phosphatase-targeting subunit
1 (MYPT1) (Amano et al., 2010; Amin et al., 2013; Kawano
et al., 1999). The small guanosine triphosphatase (GTPase)
RhoA is most widely implicated in activating ROCK to drive cell
contraction (Charras et al., 2006; Costigliola et al., 2010; Gutjahr
et al., 2005; Sahai andMarshall, 2003; Sanz-Moreno et al., 2008).
However, ROCK can also interact with the closely related
GTPase RhoC, which is known to promote ameboid-based
motility, tumor invasion, and metastasis (Clark et al., 2000; Ha-
kem et al., 2005; Kitzing et al., 2010; Leung et al., 1996; Ruth
et al., 2006; Sahai and Marshall, 2002; Simpson et al., 2004).
Cell contraction and membrane blebbing are also frequently
observed as part of the cytopathic effect induced by many
different viruses during their replication cycles (Agol, 2012). For
example, within a few hours of vaccinia virus infection, cells
begin to contract and bleb, in a process that is independent ofª 2017 The Francis Crick Institute. Published by Elsevier Inc. 315
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Vaccinia Stimulates F11-Dependent Cell Contraction
(A) Phase-contrast images showing the morphology of HeLa cells at the indicated time points (hours:minutes) after infection with WR or the DF11L virus (see
Movie S1). Scale bar, 30 mm.
(B) Phase-contrast images, 20 s apart, showing WR-induced bleb formation in HeLa cells 3 hr 40 min after infection. Scale bar, 5 mm.
(legend continued on next page)
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apoptosis (Bablanian et al., 1978; Barry et al., 2015; Schepis
et al., 2006; Schramm et al., 2006). Previous observations
suggest the vaccinia protein F11, which is expressed early
in infection, is involved in vaccinia-induced cell contraction
and/or the loss of cell-cell adhesion (Cordeiro et al., 2009; Mo-
rales et al., 2008; Valderrama et al., 2006). F11 downregulates
RhoA signaling in the latter stages of the virus replication cycle
(Arakawa et al., 2007b; Cordeiro et al., 2009; Valderrama et al.,
2006). F11 binds directly to GTP-bound RhoA using a motif
that is conserved in ROCK (Cordeiro et al., 2009; Valderrama
et al., 2006). Once bound, RhoA is inactivated by the Rho
GTPase-activating protein (RhoGAP) activity of myosin-9A,
which binds to the central PDZ-like domain of F11 via its C-ter-
minal PDZ-binding motif (Handa et al., 2013). Ultimately, F11-
mediated inhibition of RhoA signaling late during viral replication
promotes the spread of vaccinia infection by stimulating cell
migration, increasing microtubule dynamics, and enhancing
viral release by modulating the cortical actin beneath the plasma
membrane (Arakawa et al., 2007a, 2007b; Cordeiro et al., 2009;
Handa et al., 2013; Valderrama et al., 2006). Consistent with its
role during vaccinia virus infection, ectopic expression of F11
can enhance the cell-to-cell spread and oncolytic potential of
myxoma virus, which lacks F11 (Irwin and Evans, 2012; Irwin
et al., 2013).
Previous studies on F11 have largely focused on its role in in-
fected cells at 8–20 hr post infection (hpi) (Arakawa et al., 2007a,
2007b; Cordeiro et al., 2009; Handa et al., 2013; Valderrama
et al., 2006). However, F11 expression correlates with the onset
of virus-induced cell contraction (Cordeiro et al., 2009; Morales
et al., 2008). With this in mind, we set out to investigate whether
and how F11 plays a role in vaccinia-induced cell contraction
and blebbing. We found that vaccinia stimulates cell contraction
independently of RhoA by activating RhoC-mediated signaling
to ROCK. Furthermore, the ability of RhoC to promote this effect
depends on F11-mediated inhibition of RhoD signaling to Pak6.
RESULTS
F11 Induces Cell Contraction Early during Vaccinia
Infection
In agreement with earlier studies, live-cell imaging demonstrates
that within the first few hours of infection the Western Reserve
(WR) strain of vaccinia induces contraction and blebbing of
HeLa cells (Figures 1A and 1B; Movie S1). Quantification of the
cell area reveals that maximum contraction and blebbing occurs
approximately 3 hr 40 min post infection, after which time in-
fected cells begin to respread (Figures 1C and 1D). Vaccinia-
induced cell contraction is not specific to HeLa cells, as it is
also seen in U-2 OS cells (Figure S1A). In contrast, infection
with WR lacking the F11L gene (DF11L virus) does not induce(C) Quantification of the average area of HeLa cells infected with WR (black) or DF
acquisition.
(D) Quantification of the percentage of WR-infected cells blebbing at the indicate
(E) Images showing the association of GFP-F11 with the plasmamembrane in cells
provides a volume marker (see Movie S2). Scale bar, 5 mm.
(F) Immunoblot analysis with two different F11 antibodies reveals the level of endo
WR. A36 and Grb2 represent viral and HeLa cell loading controls, respectively.
Error bars in graphs represent the SEM from three independent experiments, incells to contract or bleb (Figures 1A, 1C, and S1A). In agreement
with Schepis et al. (2006), we also found that the highly attenu-
ated virus strain, Modified Vaccinia Ankara (MVA), which does
not express a functional F11, did not induce HeLa cell contrac-
tion early during infection (Figure S1B). Using a recombinant vi-
rus expressing GFP-tagged F11 from its endogenous promoter,
we found that F11 associates with the plasma membrane,
consistent with a possible role in regulating the actin cortex (Fig-
ure 1E and Movie S2). Immunoblot analysis of WR-infected cells
confirmed that the onset of cell contraction correlates with the
expression of F11 (Figure 1F). Moreover, respreading correlates
with a gradual loss of F11, suggesting that its presence promotes
vaccinia-induced cell contraction. Consistent with this, pro-
longed expression of F11 in U-2 OS cells suppresses their
respreading at later time points (Figure S1A). A role for F11 in
promoting cell contraction is unexpected, given previous obser-
vations demonstrating that the viral protein inhibits, rather than
activates, RhoA signaling.
Vaccinia-Induced Cell Contraction Depends on ROCK
It is well established that RhoA signaling to ROCK promotes
myosin-II-mediated cell contraction and blebbing by phosphor-
ylating MLC and also inhibiting MYPT1 (Amin et al., 2013; Julian
and Olson, 2014). To investigate whether ROCK is also required
for vaccinia-induced cell contraction, we infected cells in the
presence of one of three different ROCK inhibitors. In all cases,
we found that there was a dramatic inhibition in virus-induced
cell contraction, consistent with the reduction in MLC2 and
MYPT1 phosphorylation seen in immunoblots (Figures 2A and
S2A). Lack of cell contraction was not due to an inhibition of viral
entry, as the drug treated cells were equally as well infected as
control cells (Figure S2B). To extend our pharmacological anal-
ysis, we examined the impact of small interfering RNA (siRNA)-
mediated depletion of ROCK1 and ROCK2 on virus-induced
cell contraction. Independent knockdown of either kinase did
not significantly impair cell contraction (Figures 2B and S2C).
When both proteins were depleted, early viral protein expression
was not impaired but there was a substantial inhibition of cell
contraction (Figures 2B and S2D). To explore whether additional
signaling pathways also contribute to myosin-II activation, we
treated cells with siRNA against myotonic dystrophy kinase-
related Cdc42-binding kinases (MRCKa/b) and zipper-interact-
ing protein kinase (ZIPK) (Nehru et al., 2013; Usui et al., 2014;
Zhao and Manser, 2015). We found that WR-infected cells still
contract in the absence of MRCKa/b and ZIPK (Figures 2C and
2D). In addition, we treated infected cells with ML7 or ML9 to
inhibit MLC kinase (MLCK) to examine whether it also partici-
pates in virus-driven cell contraction. Consistent with a role for
myosin-II during viral entry (Mercer and Helenius, 2008), we
found that inhibition of MLCK with ML7 or ML9 dramatically11L (red) over 11 hr. Each cell area is normalized to its initial value at the start of
d times post infection.
infected withWR for 3 hr 40min. The time is indicated in seconds andmCherry
genous F11 expression in HeLa cells at the indicated times after infection with
which a total of 60 cells were analyzed. See also Figure S1.
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Figure 2. Vaccinia-Induced Cell Contraction Is Dependent on ROCK Signaling
(A) Images of HeLa cells infected withWR for 3 hr 40 min in the absence (DMSO) or presence of ROCK inhibitors (GSK49286A, H1152, and Y27632) together with
quantification of cell area. Scale bar, 30 mm.
(B) Images showing the morphology of HeLa cells treated with siRNA against ROCK1 and ROCK2 at 3 hr 40 min post infection with WR together with quanti-
fication of cell area. Scale bar, 30 mm.
(legend continued on next page)
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Figure 3. Vaccinia-Mediated Cell Contrac-
tion Is Not Dependent on RhoA
(A) Phase-contrast images of HeLa cells infected
with the F11-VK virus and quantification of their
average area (blue line). The F11-VK infection was
performed at the same time as WR (black line) and
DF11L (red line) taken from Figure 1A.
(B) Images of HeLa cells infected with WR treated
with non-targeting (NT) control or RhoA siRNA,
together with quantification of their average area.
The immunoblot shows the efficiency of RhoA
knockdown, and a-tubulin represents a loading
control.
(C) Representative images of HeLa cells infected
with WR in the presence or absence of the C3
Rho inhibitor, together with quantification of their
average area.
All scale bars, 5 mm. Error bars represent the SEM
from three independent experiments, in which a
total of 60 (A), 80 (B), and 100 (C) cells were
analyzed. See also Figure S3.reduced early viral protein expression (Figure 2E). To overcome
this inhibition, we infected cells in the presence of cycloheximide
to block viral uncoating (Mercer et al., 2012), before adding
ML7 or ML9 (Figure 2F). Removal of the cycloheximide in the
presence of ML7 or ML9 restarts the stalled replication cycle,
resulting in early viral protein expression and cell contraction
(Figure 2F). Taken together, our results indicate that ROCK-
mediated regulation of myosin-II is required for vaccinia-induced
cell contraction and that both isoforms are functionally redun-
dant. The global levels of phospho-MLC did not appreciably(C) The graphs show the percentage of remaining MRCKa, MRCKb, or ZipK mRNA following treatment with
AllStar control (NT). The Immunoblot shows the level of MRCKa and ZipK after siRNA treatment. A36 and MC
respectively.
(D) Quantification of the average area of HeLa cells infected with WR for 3 hr 40 min and treated with the ind
(E) Immunoblot analysis at 5 hpi reveals that in contrast to the ROCK inhibitors, ML7 andML9 suppress viral en
(A36). MLC represents a cell loading control.
(F) Immunoblot analysis demonstrates that washout of cycloheximide at 2 hpi in the presence or absence of
expression of F11 and A36. Actin and Grb2 represent loading controls. The graph reveals that after cyclohe
the presence of ML7 and ML9.
Error bars in graphs represent the SEM from three independent experiments in which a total of 60–100 cells w
also Figure S2.
Developchange during WR or DF11L virus
infection, but the subcellular distribution
of phospho-MLC was strikingly different
(Figures S2A and S2E). Live-cell imag-
ing also reveals that RFP-MLC2 is re-
cruited to the blebbing cell cortex (Fig-
ure S2F and Movie S3), suggesting that
localized ROCK activity drives the redis-
tribution of myosin-II to promote cell
contraction.
Vaccinia Promotes RhoC- but Not
RhoA-Dependent Cell Contraction
Given the involvement of ROCK1/2,
we wondered whether an interaction
of F11 with RhoA is also required for vi-
rus-induced cell contraction. To addressthis question, we infected cells with a recombinant virus ex-
pressing F11-VK, which is defective in RhoA binding (Cordeiro
et al., 2009). We found that the F11-VK virus is as effective
as the parental WR strain in inducing cell contraction (Figure 3A
andMovie S1). Furthermore, siRNA-mediated depletion of RhoA
did not impact on the ability ofWR to induce cell contraction (Fig-
ure 3B). In contrast, the Clostridium botulinum toxin C3, a pan-
RhoA, B, and C inhibitor (Aktories, 2011), blocked virus-induced
cell contraction but not infection (Figures 3C and S3). This sug-
gests that vaccinia-induced cell contraction is independent ofthe indicated siRNA relative to the non-targeting
M7 represent viral and HeLa cell loading controls,
icated siRNA.
try based on reduced early viral protein expression
ML7 and ML9 does not inhibit viral entry based on
ximide washout WR-infected cells still contract in
ere analyzed. ***p < 0.001; ns, not significant. See
mental Cell 41, 315–329, May 8, 2017 319
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Figure 4. RhoC Is Required for Vaccinia-
Induced Cell Contraction
(A) Immunoblot analysis of glutathione pull-downs
on WR-infected HeLa cell lysates reveals that
GST-F11 interacts with GFP-tagged RhoA, RhoC,
RhoD, RhoE, and RhoF.
(B) Quantification of the area of HeLa cells treated
with the indicated siRNA at 3 hr 40 min post
infection with WR.
(C) Quantification of the area of HeLa cells ex-
pressing GFP or GFP-tagged wild-type (WT) or
T19N (dominant-negative) RhoC 3 hr 40 min after
infection with WR (left) or DF11L (right).
(D) Images showing the association of GFP-RhoC
with the plasma membrane in cells infected with
WR for 3 hr 40 min. The time is indicated in sec-
onds and mCherry provides a volume marker (see
Movie S4). Scale bar, 5 mm.
(E) Quantification of WR-infected HeLa cell area
at 3 hr 40 min post infection in the presence or
absence of C3, 72 hr after treatment with the
indicated siRNA.
(F) Normalized cell area of WR-infected HeLa cells
at 3 hr 40 min post infection, 72 hr after treatment
with the indicated siRNA.
Error bars in graphs represent the SEM from
three independent experiments, in which a total of
90 (B), 60 (C), and 80 (E and F) cells were analyzed.
*p < 0.05, **p < 0.01, ***p < 0.001; ns, not signifi-
cant. See also Figure S4.RhoA but reliant on the activation of ROCK by another
RhoGTPase.
Previous studies have linked RhoB, RhoC, RhoD, RhoE, and
RhoF (Rif) to ROCK signaling (Fan et al., 2010; Leung et al.,
1996; Riento and Ridley, 2003; Tsubakimoto et al., 1999). Given
this finding, we examined whether F11 also interacts with these
RhoGTPases. Pull-down assays on lysates from infected HeLa
cells demonstrate that glutathioneS-transferase (GST)-F11asso-
ciates with GFP-tagged RhoC, D, E, and F but not RhoB or Rac
(Figure 4A). To examine whether any of these RhoGTPases are
required for vaccinia-induced cell contraction, we performed
siRNA-mediated ablation of each protein (Figures S4A and
S4B). We found that only depletion of RhoC had a significant
impact on the ability of WR to induce cell contraction (Figure 4B).
Consistent with the lack of involvement of RhoA, the combined
loss of RhoA and RhoC did not result in a greater inhibition of
WR-induced cell contraction than RhoC alone (Figures 4B
andS4A). In addition, expressionofGFP-taggeddominant-nega-320 Developmental Cell 41, 315–329, May 8, 2017tive RhoC-T19N blocked WR-mediated
cell contraction (Figure 4C). In contrast,
expression of GFP-RhoC stimulated par-
tial contraction of DF11L virus-infected
cells (Figure 4C). In agreement with its
role in promoting cell contraction, RhoC
is associated with the plasma membrane
of blebs (Figure 4D and Movie S4). The
involvement of RhoC explains why C3
toxin blocks WR-induced cell contraction
(Figure 3C). Moreover, C3 treatment did
not increase the suppression of cellcontraction induced by the loss of RhoC (Figure 4E). To confirm
that RhoC acts via ROCK to promote contraction of infected
cells,wedepletedbothRhoCandROCK1/2.Depletion of all three
proteins impaired WR-induced cell contraction to the same
extent as the loss of ROCK1/2 or RhoC alone (Figure 4F). Our ob-
servations demonstrate that vaccinia-induced cell contraction in-
volves RhoC-mediated activation of ROCK.
F11-Mediated Inhibition of RhoDPromotes RhoC-Driven
Cell Contraction
It is well established that RhoGTPases frequently regulate
each other (Guilluy et al., 2011). Given their interaction with F11,
it is possible that RhoD, RhoE, and RhoF may have an inhibitory
role in promoting vaccinia-induced cell contraction. We found
that loss of RhoD but not RhoE or RhoF results in contraction
of DF11L virus-infected cells (Figures 5A and S5A). Moreover,
this contraction has temporal dynamics similar to those of
WR-induced cell contraction (Figure 5B). GFP-tagged RhoD is
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Figure 5. RhoD Negatively Regulates Vaccinia-Stimulated Cell Contraction
(A) Quantification of the area of HeLa cells treated with the indicated siRNA for 72 hr at 3 hr 40 min post infection with the DF11L virus.
(B) Quantification of the change HeLa cell area after treatment with RhoD siRNA and infection with the DF11L virus.
(legend continued on next page)
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associated with the plasma membrane of vaccinia-induced
blebs (Figure 5C and Movie S5) and can also interact with GST-
F11-VK in lysates from infected cells (Figure S5B). Furthermore,
in vitro pull-down assays with recombinant proteins demonstrate
that F11 interacts directly with RhoD (Figure S5C). We further
examined the impact of expressing siRNA-resistant GFP-tagged
wild-type (WT), constitutively active (G26V), or dominant-negative
(T31N) RhoD on DF11L-infected cells treated with RhoD siRNA.
GFP-tagged RhoD or its constitutively active G26V mutant sup-
pressed the contraction of DF11L-infected cells induced by the
depletion of endogenous RhoD (Figure 5D). In contrast, GFP-
RhoD-T31N did not inhibit cell contraction. Taken together, these
data suggest that RhoD and RhoC have an antagonistic role
during vaccinia-mediated cell contraction. While the presence
of RhoC and activity of ROCK are required for F11-induced cell
contraction, RhoD must be inactive or absent. Consistent with
this, GFP-RhoD-G26V, but not the dominant-negative T31N
mutant, suppressed contraction ofWR-infected cells (Figure 5D).
To determinewhether RhoDandRhoC areworking in the sameor
parallel pathways,we investigatedwhether pharmacological inhi-
bition of ROCK, or C3-mediated loss of RhoC signaling, sup-
presses contraction of DF11L-infected cells that lack RhoD.
Indeed, both inhibitors blocked contraction of DF11L-infected
cells treated with RhoD siRNA (Figure 5E). Furthermore, DF11L-
infected cells did not contract in the absence of both RhoC
and RhoD, following siRNA silencing of both proteins (Figure 5F).
Curiously, loss of RhoA, which promotes the spreading ofDF11L-
infectedcells,waspartially able to suppress the impact of the loss
of RhoD during DF11L infection (Figure S5D). Notwithstanding
this, taken together our results demonstrate that F11 facilitates
RhoC-mediated contraction of WR-infected cells by inhibiting
RhoD signaling. Moreover, in non-infected cells expression
of dominant-negative GFP-RhoD-T31N increases the level of
GTP-boundRhoC, confirming that RhoDcan inhibit RhoC activity
outside the context of vaccinia infection (Figure 5G).
Our previous observations demonstrated that RhoA is inacti-
vated by the RhoGAP activity of myosin-9A, which interacts
with F11 (Handa et al., 2013). It is possible that myosin-9A bound
to F11 also inhibits RhoD signaling. However, this does not
appear to be the case, as WR still induces contraction of cells
treated with myosin-9A siRNA (Figure S5E). Furthermore, unlike
RhoD siRNA, loss of myosin-9A does not induce contraction of
DF11L-infected cells (Figure S5E).
RhoD Inhibits RhoC Signaling via Pak6
There are many documented examples and different mecha-
nisms regulating RhoGTPase crosstalk (Guilluy et al., 2011).(C) Images showing the association of GFP-RhoD with the plasma membrane in
mCherry provides a volume marker (see Movie S5). Scale bar, 5 mm.
(D) Left graph shows the quantification of the area of HeLa cells, treated with R
active), or T31N (dominant-negative) RhoD and infected with DF11L at 3 hr 40 m
tagged G26V (constitutively active) or T31N (dominant-negative) RhoD and infec
(E) The area of RhoD-depleted HeLa cells, with or without H1152 (top) or C3 (bo
(F) The area of HeLa cells depleted of RhoD or RhoD and RhoC and infected with
RhoD and RhoC knockdown, and actin represents a loading control.
(G) The graph shows the level of GTP-bound RhoC in non-infected U-2 OS cells
from four independent experiments. The immunoblot illustrates a representative
Error bars in cell-area graphs represent the SEM from three independent experime
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.
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vated kinase family members, Pak1 and Pak4, which phosphor-
ylate and inhibit a number of different Rho guanine nucleotide
exchange factors (RhoGEFs) to prevent RhoA activation (Barac
et al., 2004; Nimnual et al., 2003; Rosenfeldt et al., 2006).
Pak5, a class II family member, is also one of a few known
RhoD binding partners (Wu and Frost, 2006). Given this informa-
tion, we decided to investigate whether Pak family kinases
mediate the antagonistic crosstalk between RhoD and RhoC.
We found that pharmacological inhibition of the class I family
members Pak1–3 with IPA3 did not stimulate contraction of
DF11L-infected cells (Figure S6A). In contrast, siRNA-mediated
loss of Pak6 but not Pak4 or Pak5 results in cell contraction (Fig-
ures 6A, S6B, and S6C). Furthermore, GFP-tagged Pak6 but
not Pak4 or Pak5 associates with the plasma membrane of
blebs (Figure 6B and Movie S6). The DF11L-induced contraction
of cells treated with Pak6 siRNA is specific, as it is inhibited
by expression of siRNA-resistant GFP-PAK6 (Figure 6C). In
contrast, the Pak6-K436A kinase-dead mutant did not suppress
contraction of DF11L-infected cells treated with Pak6 siRNA
(Figure 6C). In agreement with this, GFP-PAK6, but not its
kinase-dead mutant, blocked WR-induced cell contraction
(Figure 6C).
To confirm that Pak6 acts upstream of RhoC and ROCK,
we examined the impact of inhibiting RhoC or ROCK with C3
and H115, respectively, in DF11L-infected cells depleted of
Pak6. In both cases, DF11L-induced contraction of cells lacking
Pak6was suppressed (Figure 6D). Cells simultaneously depleted
of Pak6 and RhoC also failed to contract (Figure 6D). To examine
whether Pak6 and RhoD act in the same pathway to inhibit
RhoC/ROCK signaling, we expressed GFP-tagged RhoD or
Pak6 in cells depleted of endogenous Pak6 or RhoD, respec-
tively. We found that the ability of GFP-RhoD to inhibit contrac-
tion of WR-infected cells depends on the presence of Pak6 (Fig-
ure 6E). In contrast, GFP-Pak6 blocks WR-induced contraction
in the presence or absence of RhoD (Figure 6E). Our data
demonstrate that RhoD acts through Pak6 to inhibit RhoC-medi-
ated cell contraction.
RhoD Interacts with Pak6 and Mediates Its Recruitment
to the Plasma Membrane
It is thought that RhoGTPases regulate class II Pak kinases by
controlling their subcellular location rather than directly stimu-
lating their kinase activity (Ha et al., 2015). We therefore exam-
ined whether RhoD is required to recruit Pak6 to the plasma
membrane. We found that there was a dramatic reduction in
the association of GFP-Pak6with the plasmamembrane of blebscells infected with WR for 3 hr 40 min. The time is indicated in seconds and
hoD siRNA and expressing GFP-tagged wild-type (WT), G26V (constitutively
in post infection. Right graph shows the area of HeLa cells expressing GFP-
ted with WR for 3 hr 40 min.
ttom) treatment, and infected with DF11L at 3 hr 40 min post infection.
DF11L at 3 hr 40 min post infection. The immunoblot shows the efficiency of
expressing GFP, GFP-RhoD G26V, or T31N mutant. Error bars represent SEM
assay.
nts, in which a total of 90 (A and B), 70 (E), and 60 (D and F) cells were analyzed.
A B
C
D E
Figure 6. Pak6 Inhibits RhoC-Driven Cell Contraction
(A) Quantification of the area of HeLa cells treated for 72 hr with the indicated siRNA and infected with the DF11L virus for 3 hr 40 min.
(B) Images showing the subcellular localization of GFP-tagged Pak4, Pak5, and Pak6 during WR infection. Only GFP-Pak6 is associated with the plasma
membrane, and mCherry provides a volume marker (see Movie S6). Scale bar, 5 mm.
(C) Quantification of the area of WR- or DF11L-infected HeLa cells treated with Pak6 siRNA and expressing GFP-tagged WT or kinase-dead (KD) Pak6.
(D) The area of Pak6 depleted HeLa cells infected with DF11L at 3 hr 40 min post infection and treated with H1152, C3, or RhoC siRNA.
(E) The area of WR-infected HeLa cells depleted of RhoD or Pak6 and expressing GFP-tagged Pak6 or RhoD, respectively.
Error bars in graphs represent the SEM from three independent experiments, in which a total of 90 (A and D) or 60 (C and E) cells were analyzed. *p < 0.05,
**p < 0.01, ***p < 0.001; ns, not significant. See also Figure S6.
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Figure 7. RhoD Interacts Directly with Pak6
(A) Images showing that siRNA-mediated ablation
of RhoD leads to a loss of GFP-Pak6 recruitment
to the plasma membrane in cells infected with
DF11L. In contrast, loss of Pak6 does not impact
on recruitment of GFP-RhoD to the plasma
membrane (see Movie S7). Scale bar, 5 mm.
(B) Immunoblot analysis with the indicated anti-
bodies of a GFP-Trap pull-down on cell lysates
from uninfected HeLa expressing Myc-RhoD and
GFP-Pak6 or GFP-RhoD and Myc-Pak6.
(C) Immunoblot of glutathione-Sepharose pull-
downs on HeLa cell lysates demonstrates that
GST-Pak6 interacts with RhoD, while Rhotekin
preferentially associates with RhoA and RhoC.
(D) Immunoblot of glutathione-Sepharose pull-
downs with recombinant proteins demonstrates
that GST-Pak6 interacts with RhoD but not RhoA
or RhoC.
See also Figure S7.in DF11L-infected cells treated with RhoD siRNA (Figure 7A and
Movie S7). In contrast, loss of Pak6 had no obvious impact on
the recruitment of GFP-RhoD to the plasma membrane (Fig-
ure 7A and Movie S7). These data suggest that RhoD interacts
with Pak6 to recruit the kinase to the plasmamembrane. Consis-
tent with this, reciprocal pull-downs on myc- and GFP-tagged
RhoD and Pak6 demonstrate that the two proteins interact
with each other in uninfected cells (Figure 7B). Recombinant
GST-Pak6 can also retain RhoD but not RhoC or RhoA from
cell lysates (Figures 7C and S7A). Moreover, pull-down assays
with recombinant proteins demonstrate that the interaction be-
tween RhoD and Pak6 is direct (Figures 7D and S7B). Our data
clearly demonstrate that RhoD inhibits RhoC-ROCK-induced
cell contraction via its downstream effector Pak6.324 Developmental Cell 41, 315–329, May 8, 2017DISCUSSION
The organization and contraction of
the cortical actin cytoskeleton plays an
essential role in controlling cell shape
and movement during development and
tumor cell invasion (Blaser et al., 2006;
Charras and Paluch, 2008; Fackler and
Grosse, 2008; Friedl and Wolf, 2003; Pal-
uch and Raz, 2013; Sahai and Marshall,
2003;Sanz-Morenoet al., 2008;Tozluoglu
et al., 2013; Zatulovskiy et al., 2014).While
it is well established that myosin-II drives
contraction of the actin cortex, we still
lack a complete understanding of the or-
ganization and composition of the cortical
actin cytoskeleton, aswell as the signaling
networks controlling its form and function
(Barry et al., 2015; Biro et al., 2013; Bovel-
lan et al., 2014; Fritzsche et al., 2013,
2016). One of the hallmarks of myosin-II-
driven contraction of the actin cortex is
the formationof blebsat theplasmamem-
brane (Charras et al., 2008). Cell blebbing,which occurs during ameboid-based cell motility, mitotic round-
ing, and cytokinesis (Friedl and Wolf, 2003; Matthews et al.,
2012; Sedzinski et al., 2011), is also frequently seen as part of
the so-called cytopathic effect during many different viral infec-
tions (Agol, 2012). In the case of vaccinia virus, cells start to con-
tract and bleb within a few hours of infection (Bablanian et al.,
1978; Barry et al., 2015; Schepis et al., 2006; Schramm et al.,
2006). We have now demonstrated that vaccinia-induced cell
contraction and blebbing is dependent on the viral protein F11.
The ability of F11 to induce ROCK-dependent cell contraction
early during viral replication contrasts with its ability to inhibit
RhoA signaling in the latter stages of infection (Arakawa et al.,
2007b; Cordeiro et al., 2009; Handa et al., 2013; Valderrama
et al., 2006). F11-mediated inhibition of RhoA signaling at 8 hpi
stimulates infected cell migration and also facilitates the release
of new viral progeny by increasing microtubule growth toward
theplasmamembraneandmodulating thecortical actin cytoskel-
eton (Arakawa et al., 2007a, 2007b; Cordeiro et al., 2009; Handa
et al., 2013; Morales et al., 2008; Valderrama et al., 2006).
Considering the ability of RhoA to bind F11, it was surprising
that F11-induced cell contraction depends on RhoC and not
RhoA, as both GTPases have been shown to bind and activate
ROCK to induce actin stress fiber formation and myosin-II
contraction (Leung et al., 1996; Ridley, 2013). Historically it has
been difficult to assign individual effects or cellular responses
to RhoA and RhoC, in part because, until relatively recently,
most studies tended to focus only on RhoA. Furthermore,
expression of constitutively active or dominant-negative RhoA
mutants impacts on the activity of both GTPases, as does the
inhibitory effect of C3 toxin (Aktories, 2011). More recently, the
use of RNAi-based approaches has begun to uncover distinct
functions for RhoA and RhoC (Bravo-Cordero et al., 2011,
2013; Korkina et al., 2013; Sahai and Marshall, 2003; Vega
et al., 2011). However, it is striking that the evidence for RhoA
driving cell contraction and blebbing is largely based on the
use of reagents that do not fully discriminate between RhoA
and RhoC (Charras et al., 2006; Costigliola et al., 2010; Gutjahr
et al., 2005; Sahai and Marshall, 2003; Sanz-Moreno et al.,
2008). Our observations demonstrate that RhoC plays the
greater role in stimulating ROCK-mediated myosin-II contraction
of the actin cortex during vaccinia infection. This conclusion
has important implications for a variety of cellular processes
involving cell contraction and blebbing that have previously
only been assigned to RhoA. It is also striking that there is
more evidence suggesting that RhoC is more important than
RhoA in promoting tumor cell invasion and metastasis (Clark
et al., 2000; Dietrich et al., 2009; Hakem et al., 2005; Kitzing
et al., 2010; Leung et al., 1996; Ridley, 2013; Ruth et al., 2006;
Sahai and Marshall, 2002; Simpson et al., 2004).
F11 interacts directly with RhoA using a motif that is similar to
thatof theRho-bindingsite inROCK (Cordeiro et al., 2009;Valder-
rama et al., 2006). It is likely that F11 will also bind directly to
RhoC, as its effector binding switchI/II regions are essentially
identical to those in RhoA (Ridley, 2013; Wheeler and Ridley,
2004). Our in vitro pull-down assays with recombinant protein
reveal that RhoC interacts much less efficiently with F11 than
with RhoA (Figure S5C). The reason for this dramatic difference is
not immediately obvious. However, we found that F11 regulates
RhoC-mediated cell contraction by inhibiting RhoD signaling.
RhoD is emerging as a RhoGTPase family member with diverse
functions including regulation of centrosomeduplication, cell-cy-
cle progression, actin structures, andmembrane trafficking (Gas-
man et al., 2003; Koizumi et al., 2012; Kyrkou et al., 2013; Nehru
et al., 2013). Previous analysis demonstrates that overexpression
of constitutively active RhoD disrupts focal adhesions and stress
fibers, and also suppresses the ability of active RhoA to promote
actin assembly (Tsubakimoto et al., 1999). These overexpression
data led the authors to suggest that RhoD antagonizes RhoA
signaling (Tsubakimoto et al., 1999).Our data nowclearly demon-
strate that RhoD antagonizes the function of RhoC, which repre-
sents another example of RhoGTPase crosstalk, whereby the
action of one GTPase regulates the activity of another. GTPase
crosstalk can regulateRhoGEFsandRhoGAPs,GTPase stability,and downstream signaling (reviewed in Guilluy et al., 2011). One
well-documented example of GTPase crosstalk is the inhibition
of RhoA by Rac. Following Rac activation, the downstream effec-
tors Pak1 and Pak4 phosphorylate p115-RhoGEF, GEF-H1,
PDZ-RhoGEF, and Net1 (Alberts et al., 2005; Barac et al., 2004;
Rosenfeldt et al., 2006; Zenke et al., 2004). Phosphorylation of
these RhoGEFs inhibits their exchange activity or alters their
stability and/or localization, leading to a loss of downstream
RhoA activation. There remains the possibility that Pak1 and
Pak4 can also control RhoC-mediated cell contraction, as some
of these RhoGEFs also regulate the activity of RhoC (Jaiswal
et al., 2011; Ren et al., 1998). This possibility, together with the
observation that RhoD interacts with Pak5 (Wu and Frost,
2006), led us to investigate whether Pak kinases were involved
in vaccinia-induced cell contraction. We found that only deple-
tion of Pak6 stimulated RhoC/ROCK-dependent contraction of
DF11L virus-infected cells. Conversely, Pak6 overexpression
suppressed contraction of WR-infected cells. Furthermore,
RhoD suppressed WR-induced cell contraction through Pak6,
suggesting that Pak6 is a RhoD effector. Consistent with this
notion, we found that RhoD can interact directly with Pak6 and
is responsible for recruitment of the kinase to the plasma
membrane.
Our data are in agreement with previous observations sug-
gesting that RhoGTPases principally regulate class II Pak family
members by controlling their subcellular location rather than
directly stimulating their kinase activity (Ha et al., 2015). Never-
theless, our results clearly show that the kinase activity of Pak6
is required to inhibit RhoC-induced cell contraction. It is possible
that Pak6 may directly phosphorylate RhoC to regulate its activ-
ity. Seven of the 22 RhoGTPases, including RhoA, have a serine
residue between their phospholipid-binding polybasic region
and the CAAX motif that can be phosphorylated (Wheeler and
Ridley, 2004). Phosphorylation of this serine weakens the asso-
ciation of the RhoGTPase with themembrane and also increases
its affinity for Rho GDP-dissociation inhibitor (RhoGDI), which
extracts the GTPase from membrane (Boulter et al., 2010; Eller-
broek et al., 2003; Garcia-Mata et al., 2011). However, RhoC
does not have an equivalent serine residue between its polybasic
region and CAAX motif, so is unlikely to be regulated by this
mechanism. Furthermore, our pull-down assays demonstrate
that Pak6 does not interact with RhoC. Given this finding it
may be that, as with Rac-mediated inhibition of RhoA, Pak6
suppresses the activity of RhoC by phosphorylating one or
more RhoGEF. This raises the question of how specificity of a
RhoGEF(s) for RhoC over RhoA is achieved. The RhoGEF bind-
ing switch I regions of RhoA, B, and C are almost identical, with
only a single change for RhoB (Q29E) or RhoC (V43I) (Wheeler
and Ridley, 2004). Structural analysis of RhoA in complex with
the LARG, PDZ-RhoGEF, or p63RhoGEF reveals that Val43 par-
ticipates in van der Waals interactions at the RhoGTPase:GEF
interface (Chen et al., 2010; Kristelly et al., 2004; Lutz et al.,
2007; Oleksy et al., 2006). A bulkier isoleucine residue at
this point could sterically block the interaction between the
RhoGTPase and its GEF. Indeed, the GEF XPLN interacts with
RhoA and RhoB but not RhoC, the distinguishing feature being
the isoleucine residue at position 43 in RhoC (Arthur et al.,
2002; Sloan et al., 2012). Conversely, it is also conceivable that
RhoD/Pak6 can activate a GAP capable of downregulatingDevelopmental Cell 41, 315–329, May 8, 2017 325
RhoC signaling. We previously found that RhoA is inactivated by
the GAP activity of myosin-9A, in an F11-dependent manner in
late stages of infection (Handa et al., 2013). However, we now
found that in early stages of infection there is no role for
myosin-9A, as WR still induces cell contraction and those in-
fected with DF11L remain spread when myosin-9A is depleted
(Figure S5E). These data also suggest that myosin-9A has no
GAP activity toward RhoD.
From our studies it is clear that early during vaccinia infection
there must be an additional stimulus activating RhoC, as DF11L
virus-infected cells depleted of RhoD or Pak6 contract in an
RhoC-dependent fashion. This is consistent with our hypothesis
that in DF11L-infected cells RhoD recruits Pak6 to the plasma
membrane where it can locally antagonize RhoC signaling to
ROCK to inhibit cell contraction. Moreover, the activation of
RhoC by an additional viral protein within the first few hours of
infection might explain why F11 promotes very different pheno-
types at early and late time points during infection. It is also
possible that the selectivity of RhoC during vaccinia-induced
contraction is actually dependent on this unknown stimulus,
leaving the possibility open that Pak6 suppresses both RhoA
and RhoC signaling. The task ahead is to understand how
vaccinia activates RhoC and to use vaccinia-induced cell
contraction as an assay to uncover the basis for Pak6-mediated
inhibition of RhoC signaling.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
HeLa cells were cultured in Modified Eagle Medium (MEM) supplemented with 10% SFB, penicillin (100u/ml) and streptomycin
(100mg/ml). U-2 OS cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% SFB, penicillin
(100u/ml) and streptomycin (100mg/ml). HeLa and U2-OS cells were authenticated by STR profiling and are both negative for
mycoplasma.
Viruses and Infections
The wild-type virus used in this work is the Western Reserve strain (WR) (Cudmore et al., 1995). The recombinant viruses DF11L or
F11-VK have been previously described (Cordeiro et al., 2009). The virus encoding GFP-F11, with a GGRGG linker between the GFP
and N-terminus of F11 was generated by homologous recombination between a targeting vector encoding F12-GFP-F11 and the
DF12L virus (Dodding et al., 2009; Zhang et al., 2000; Rietdorf et al., 2001). The F12-GFP-F11 targeting vector was transfected
into HeLa cells 3 hours after infection with the DF12L virus, at a multiplicity of infection of 0.1 plaque-forming units. Two days later,
cells were harvested and ruptured by freeze thawing. The cell lysate was then used to infect confluent BSC-1 cell monolayers, which
were overlaid with 0.9% agarose 2 h after infection. Four days later, individual plaques were picked based on the rescue of theDF12L
small plaque phenotype as well as expression of GFP. The virus in the isolated plaques was then amplified by re-infecting HeLa cells
for 48 h. A further 4 rounds of plaque purification were performed until the recombinant GFP-F11 virus was clonal. The fidelity of
the recombinant virus was confirmed by sequencing. HeLa or U-2 OS cells were infected with the WR strain of Vaccinia or itse3 Developmental Cell 41, 315–329.e1–e6, May 8, 2017
recombinant F11L derivatives at a multiplicity of infection (MOI) of 5 in serum free MEM. After 20 minutes the media was replaced for
MEM +10%FBS.
METHOD DETAILS
Plasmids
GFP, GST, Myc and His-tagged Pak4, Pak5, Pak6, RhoA to RhoF and Rac1 expression constructs were generated as required by
cloning their respective ORFs into the Not1-EcoR1 sites of CB6-GFP or CB6-Myc a CMV based mammalian expression vector
(Handa et al., 2013); pMW172-GST or pMW172-His an E. coli T7 based expression vector (Boeda et al., 2007) and pEL-GFP or
pEL-GST a vaccinia expression vector (Frischknecht et al., 1999). Human RhoB and RhoF (Rif) as well as mouse RhoD templates
were a kind gift of Dr. Harry Mellor (Bristol University, UK). Human RhoC and RhoE were a kind gift of Dr. Erik Sahai (The Francis Crick
Institute, UK). Human PAK 4, 5 and 6 synthetic gene sequences were bought from GeneArt (Invitrogen). GST-F11 in pMW172 and
pEL expression vectors have been described (Valderrama et al., 2006). The pLVX CMV based mammalian expression clones for
MLC2-RFP, GFP and mCherry have been described (Barry et al., 2015). Point mutations were introduced into wild-type clones as
required using the QuikChange site directed mutagenesis kit (Stratagene).
Drug Treatments
The cell permeable Rho inhibitor (C3) (Cytoskeleton Inc. USA) was added to cells at a final concentration of 0.5mg/ml one hour prior to
infection. The ROCK inhibitors 10mMY27632 (Sigma Aldrich), 5mMH1152 or 5mMGSK429286A and the Group I p21-activated kinase
(PAK) inhibitor 10mM IPA-3 (Tocris Bioscience) were added to cells 30 minutes before infection. The Myosin Light Chain Kinase
(MLCK) inhibitors 20mMML7 or ML9 (Sigma Aldrich) were added to cells 15 minutes after viral infection in the presence or absence
of Cyclohexamide (CHX) at a final concentration of 20mg/ml. ML7 or ML9 were maintained throughout the experiment after CHX
washout at 2hpi.
siRNA and DNA Transfections
Dharmacon pools of four siRNA oligo duplexes against Pak4 (MU-003615-00), Pak5 (MU-003973-02), Pak6 (MU-004338-02), RhoA
(MU-003860-03), RhoC (MU-008555-01), RhoD (MU-008940-0), RhoE (MU-007794-02), Rif (MU-008316-00) and DAPK3/ZIPK
(MU-004947-00) were used for knockdown. In addition, two individual siRNA oligo duplexes against RhoD (oligo #1 D-008940-01
and oligo #2 D-008940-02) and Pak6 (oligo #1 D-004338-05 and oligo #2 D-004338-06) were also used. Individual oligos were
also used to deplete Myosin-9A (D-006539-01 and D-006539-03), ROCK1 (D-003536-05) and ROCK2 (D-004610-05) as previously
described (Pinner and Sahai, 2008). MRCKa and b were depleted using siRNA MRCK1 (CGAGAAGACTTTGAAATAA) targeting both
isoforms andMRCK2 targetingMRCKa (AAGAATATCTGCTGTGTTT) andMRCKb (GAAGAATACTGAACGAATT) as described inWil-
kinson et al., 2005. HeLa cells were transfected with 20nM of siRNA using the HiPerFect fast-forward protocol (Qiagen). After three
days, the cells were processed for immunoblotting, RT-qPCR or infected with vaccinia virus for live cell imaging. Sixteen hours prior
to infection, HeLa cells were transfected with the indicated expression vectors using Fugene6 (Roche).
Reverse Transcription Quantitative PCR (RT-qPCR)
Total RNA was extracted from HeLa cell lysates using the RNeasy Mini kit (Qiagen) according to the manufacturer’s protocol. RNA
was converted to cDNA using SuperScript II reverse transcriptase (Applied Biosystems). cDNA was amplified by quantitative PCR
using Power SYBR Green reagents and 7500 Fast Real-Time PCR System (Applied Biosystems). The level of mRNA of the gene
of interest (GOI) was normalized to GAPDHmRNA and normalized GOI mRNA in knockdown samples was compared to AllStar con-
trol sample (NT) using the comparative Ct method.
Purification of Recombinant Proteins
The expression vector pMW-GST-F11 was transformed into E. coli BL21-Codon Plus (DE3)-RIL (Agilent Technologies) and ex-
pressed for 16h at 30C. Cells were collected by centrifugation, resuspended in bacterial lysis buffer [50mM Tris-HCl pH8.0,
150mM NaCl, 1mM EDTA, 0,1% Triton-X, 25% sucrose, protease inhibitor cocktail (Roche)] and lysed by sonication. The soluble
fraction was collected by centrifugation and incubated with Glutathione Sepharose 4 Fast Flow beads (Amersham) for 1h at 4C.
GST-F11 coupled beads were collected by centrifugation, washed three times and resuspended in GST- wash/storage buffer
[PBSA, 250mM NaCl, 0,1% Triton-X, 10% glycerol].
The expression vector pMW-GST-Pak6 was transformed into E. coli BL21-Codon Plus (DE3)-RIL (Agilent Technologies) and ex-
pressed for 16h at 30C. Cells were collected by centrifugation, resuspended in GST-Pak6 lysis/wash buffer [PBS, 1% Triton-X,
50mM NaF, 1mM Na3VO4, 1mM PMSF, protease inhibitor cocktail (Roche, UK)] and lysed by sonication. The soluble fraction was
collected by centrifugation and incubatedwith Glutathione Sepharose 4B beads (Amersham) for 1h at 4C.GST-Pak6 coupled beads
were collected by centrifugation, washed three times with GST-Pak6 lysis/wash buffer and resuspended in GST-Pak6 Storage buffer
[50% glycerol, 20mM Tris-HCl pH7.6, 100mM NaCl and 1mM DTT].
All pMW-His Rho clones and Rac1were transformed into E. coli BL21-Codon Plus (DE3)-RIL (Agilent Technologies) and expressed
for 16h at 30C. Cells were collected by centrifugation, resuspended in bacterial lysis buffer [50mM Tris-HCl pH8.0, 150mM NaCl,
0,1% Triton-X, 1mM EDTA, 25% sucrose, protease inhibitor cocktail (Roche, UK)] and lysed by sonication. The soluble fractionDevelopmental Cell 41, 315–329.e1–e6, May 8, 2017 e4
was collected by centrifugation and imidazole at pH8.0 added to a final concentration of 50mM. The soluble fraction was then incu-
bated with Ni-NTA resin (Qiagen) for 1h at 4C. His-tagged protein coupled beads were collected by centrifugation, washed three
times with Ni wash buffer [PBSA, 250mMNaCl, 0,1% Triton-X, 50mM imidazole and 10mM b-mercaptoethanol]. Purified His proteins
were eluted from Ni beads in Ni wash buffer plus 250mM imidazole for 30 min at 4C.
Pull Downs Assays
GFP-Trap Pull Down Assays
For GFP-Trap pull down assays U2-OS cells were transfected with combinations of CB6 expression vectors encoding Myc- and
GFP-tagged RhoD and Pak6 according to the manufacturer’s protocol (Fugene6, Roche). Sixteen hours later, the transfected cells
were lysed in 50mM Tris-HCl pH7.5, 300mM NaCl, 10% glycerol, 1% Triton and protease inhibitor cocktail (Roche). Lysates were
incubated with GFP-Trap beads (ChromoTek) for 1hour at 4C, collected by centrifugation, washed three times with lysis buffer
and resuspended in 2 x SDS loading buffer.
GST Pull Down Assays
Vaccinia virus infected HeLa cells were co-transfected with pEL-GST-F11 or pEL-GST-F11-VK and pEL-GFP-tagged RhoGTPases
4 hours post infection prior to cell lysis 8 hours later. Cells were lysed in Mg2+ Lysis/Wash buffer [25mM Hepes pH7.5, 150mMNaCl,
1% NP-40, 10mMMgCl2, 1mM EDTA, 2%glycerol] supplemented with 25mM NaF, 20mM PMSF, 20mM Orthovanadate and prote-
ase inhibitor cocktail (Roche). Lysates were cleared by centrifugation and were incubated with Glutathione Sepharose 4 beads
(Amersham) for 60min at 4C, collected by centrifugation, washed three times with Mg2+ Lysis/Wash buffer and resuspended in
2 x SDS loading buffer.
Pulldowns on HeLa lysates with recombinant GST-Pak6 or GST-Rhotekin (Millipore) were performed as previously described
(Fram et al., 2014). Briefly, cells were lysed in NP-40 lysis buffer [0,5% NP-40, 50mM Tris-HCl pH7.6, 150mM NaCl, 0.1mM
EDTA, 50mMNaF, 1mMDTT and protease and phosphatase inhibitor cocktails (Roche, UK)]. Lysateswere pre-cleared by incubation
with GST-coupled Glutathione Sepharose 4 Fast Flow beads (Amersham) for 30min at 4C, then incubated with GST-Pak6 beads for
90min at 4C, collected by centrifugation, washed three times with lysis buffer and resuspended in 2 x SDS loading buffer.
Recombinant pulldown assays with recombinant His-tagged Rho proteins loaded with GTPgS and GST, GST-F11, GST-Pak6 or
GST-Rhotekin were performed as previously described (Cordeiro et al., 2009; Handa et al., 2013). Briefly, His-tagged proteins were
loaded with 10mM GTPgS for 30 minutes at 30C after addition of 10mM EDTA. Then, MgCl2 at a final concentration of 10mM was
added to the loaded His-tagged proteins, which were then incubated with GST-tagged proteins for 1h at 4C. Beads were collected
by centrifugation, washed three times with GST (when GST-F11 was used as resin) or GST-Pak6 (when GST-Pak6 was used as resin)
wash buffer and resuspended in 2 x SDS loading buffer.
Rho Activity Assays
Rhotekin pull down assays were performed on uninfected U-2 OS expressing GFP, GFP-RhoD G26V or T31N that were serum
starved for 24 hours and stimulated with 20% FBS for 5 minutes. Cells were lysed in Mg2+ Lysis/Wash buffer [25mM Hepes
pH7.5, 150mMNaCl, 1%NP-40, 10mMMgCl2, 1mM EDTA, 2%glycerol]. Lysates were pre-cleared by centrifugation and were incu-
bated with GST-Rhotekin beads (Millipore) for 45min at 4C, collected by centrifugation, washed three times with Mg2+ Lysis/Wash
buffer and resuspended in 2 x SDS loading buffer.
Immunoblotting
Proteins were loaded on NuPAGE 3-8% Tris-Acetate (for visualizing MCM-7, MRCK and MYPT) Protein Gels or NuPAGE 4-12%
Bis-Tris (all other proteins) Protein Gels (Invitrogen) and run at 150V for 90 minutes, after which time they were transferred to nitro-
cellulosemembranes using an iBlot dry blotting system (Invitrogen). Blots were thenwashed 3x 5minutes in PBS, following by block-
ing in 5%milk in PBS-T (PBS plus 0,1% Tween). Primary antibodies were then incubated in 5%BSA in PBS-T overnight at 4C. Blots
were washed 3x 5 minutes in PBS-T, following by incubation with secondary antibodies for 1 hour in 5% milk in PBS-T. Blots were
washed 3x 5 minutes in PBS-T and proteins were visualized using ECL western detection reagent (Amersham) and imaged with
X-ray films.
Live Cell Imaging
Cell Contraction Assays
Cells were seeded onto fibronectin-coated 12 well plates, transfected (if required) with 20nM of siRNA against MRCK, ROCK, ZipK,
Rho and PAK proteins using the HiPerFect fast-forward protocol (Qiagen) three days before infection, and (if required) with the indi-
cated expression vectors (pCB6GFP-RhoC, pCB6GFP-RhoD, pCB6GFP-PAK6 and their mutants variants) using Fugene6 (Roche)
sixteen hours prior to infection. When indicated, cells were treated with chemical inhibitors prior to infection as described in details in
the drug treatment section. HeLa cells were then infected with theWR strain of vaccinia or its recombinant F11L derivatives at a mul-
tiplicity of infection (MOI) of 5 in serum free MEM. After 20 minutes the media was replaced for MEM +10%FBS supplemented with
40mM HEPES and the indicated drugs and 40 minutes post infection images were acquired using a Plan-Apochromat 10x/0.25 Ph1
lens and a Photometrics Cool Snap HQ cooled CCD camera on a Zeiss Axiovert 200 Microscope every 5 minutes for 10 hours. The
systemwas controlled byMetaMorph software version 6.3r7 (Molecular Devices). The average area of infected cells was determined
at 1-hour intervals from the start of image acquisition using MetaMorph or ImageJ. The average cell area at each time point was
normalized to the original mean and in all experiments is represented as the percentage of the original cell area. All cell quantificationse5 Developmental Cell 41, 315–329.e1–e6, May 8, 2017
whereGFP-tagged proteinswere expressedwere only performed on cells with aGFP signal that was collected in parallel to the phase
images.
Localization of GFP/RFP-tagged Proteins in Blebs
Localization of GFP-tagged proteins in blebs was performed as previously described (Barry et al., 2015). Cells were seeded onto
fibronectin-coated 35-mmMatTek dishes, transfected using FuGENE 6 (Promega) with pLVX-GFP or pLVX-mCherry (as cytoplasmic
markers) and with the specific pCB6-tagged proteins constructs, and cultured overnight. Cells were then infected with a WR or
DF11L strain of vaccinia virus at a multiplicity of infection (MOI) of 5 in serum free MEM. After 20 minutes the media was replaced
with phenol red–free MEM with 10%FBS and live-cell imaging begun 3 h after infection using a Plan Apochromat 633/1.40 NA oil
objective (Carl Zeiss) in a temperature-controlled chamber at 37C. Images were captured on a Evolve 512 camera (Photometrics)
mounted on an inverted AxioObserver.Z1microscope (Carl Zeiss) as part of a custom-built spinning-disc confocal system (Intelligent
Imaging Innovations). All hardware was controlled with SlideBook software (Intelligent Imaging Innovations). Images were collected
at 1 second intervals.
Confocal Microscopy
Cells were seeded onto fibronectin-coated coverslips and cultured overnight. When indicated, cells were treated with ROCK inhibitor
H1152 prior to infection as described in details at the drug treatment section. HeLa cells were then infected with a WR or DF11L
strain of vaccinia virus at a multiplicity of infection (MOI) of 5 in serum free MEM. After 20 minutes the media was replaced for
MEM +10%FBS supplemented with H1152 when indicated. At 3 hours and 40 minutes post infection, cells were fixed with
4% PFA for 10 minutes at room temperature and washed three times with PBS. Cells were then permeabilized with 0,1% Triton
X-100 in PBS for three minutes and washed three times with PBS. Cells were incubated in blocking buffer (BB) [10mM MES
pH6.1, 150mM NaCl, 5mM EGTA, 5mM MgCl2, 5mM glucose] for 10 minutes and afterwards with pMLC-S19 primary antibody
diluted in BB for 1 hour at room temperature. Cells were then washed three times with PBS and incubated with FITC-anti-Rabbit
and Texas-Red Phalloidin diluted in BB for 30 min at room temperature. Cells were then washed three times with PBS, rinsed
with distilled water, mounted in microscopy slides using Mowiol and dried. Images were acquired using a Zeiss LSM 780 Confocal
Microscope.
QUANTIFICATION AND STATISTICAL ANALYSIS
In all graphs the data is themean value from at least three independent experiments in which 60-100 cells were analysed and the error
bars represent the standard error of themean (S.E.M.). Statistical analysis was determined using Prism 5.0 (GraphPad Software, CA).
A Student’s T-test was used to compare two data sets. When more than two data sets were analyzed a One Way ANOVA test was
performed followed by Turkey post test to compare all pairs of samples. A P value of >0.05 is not considered statistically significant.
* indicates P<0.05, ** indicates P<0.01 and *** indicates P<0.001.Developmental Cell 41, 315–329.e1–e6, May 8, 2017 e6
